Please ensure Javascript is enabled for purposes of website accessibility

Why Mallinckrodt Stock Is Soaring Today

By Keith Speights – Updated Feb 25, 2020 at 2:03PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Investors are cheering the company's deal to settle opioid-related lawsuits.

What happened

Shares of Mallinckrodt (MNK) were soaring 16.2% as of 11:08 a.m. EST on Tuesday after rising as much as 51.7% earlier in the day. The drugmaker announced its fourth-quarter results before the market opened, but the main reason behind the big gain was the company's news that it has reached an agreement in principle that would settle all open opioid-related litigation. 

So what

Mallinckrodt stock plunged by as much as 45% on Monday on reports that it was considering filing for Chapter 11 bankruptcy. The company confirmed today that a bankruptcy filing is on the table, but only for its specialty generics businesses. The drugmaker's proposed settlement would become effective after the specialty generics businesses emerged from bankruptcy. 

Businessman holding Chapter 11 bankruptcy papers

Image source: Getty Images.

The terms of the proposed deal include Mallinckrodt paying $1.6 billion to plaintiffs in opioid litigation in installments. The first payment of $300 million would be made after the company's specialty generics businesses come out of Chapter 11 bankruptcy. Another $200 million would be received one year later, with an additional $200 million to be paid on the second anniversary of the emergence from bankruptcy. Subsequent payments of $150 million would be made on the third through the eighth anniversaries of the specialty generics businesses emerging from bankruptcy.

Most of these payments would be paid to a trust, which would oversee a fund to cover costs of opioid-addiction treatment. After the emergence of Mallinckrodt's specialty generics businesses from bankruptcy, the trust would also receive warrants that allow it to buy Mallinckrodt stock at $3.15 per share. These warrants represent about 20% of the company's outstanding shares.

All in all, the deal is probably as good as Mallinckrodt was likely to get to put the opioid litigation behind it. And it's good news for investors who own the beaten-down pharmaceutical stock.

Now what

The next step is for Mallinckrodt's specialty generics businesses to file for Chapter 11 bankruptcy over the next few months. Parent company Mallinckrodt plc and its specialty-brands-related subsidiaries would not file for bankruptcy. 

In the meantime, it's business as usual for all of its subsidiaries. But if all goes as planned with the bankruptcy, it seems likely that Mallinckrodt will try to sell the specialty generics businesses.

Keith Speights has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Mallinckrodt Public Limited Company Stock Quote
Mallinckrodt Public Limited Company

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 09/27/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.